SEC ownership of Third Harmonic Bio, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001923840.

Comparable stake leader

BML Investment Partners, L.P.

Disclosed value leader

Atlas Venture Fund XI, L.P.

Comparable rows

5/21

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 2 signals
Latest 13D/G holder
BML Investment Partners, L.P.
Latest parsed ownership date
31 Mar 2026
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001923840
Issuer location
San Francisco, CA

Ownership snapshot

Top shareholders of Third Harmonic Bio, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BML Investment Partners, ...
Disclosed value leader
Atlas Venture Fund XI, L.P.
Comparable rows
5/21
Latest evidence
31 Mar 2026
13D/G 13F 3/4/5 Lead comparable stake: 8.2% 16 rows are not safely comparable across share classes. 13D/G row: BML Investment Partners, L.P. Showing 1-8 of 21 holder rows.

Quick read

BML Investment Partners, L.P. leads the comparable SEC ownership view at 8.2%.

5 of 21 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BML Investment Partners, L.P.'s linked filing trail.
Comparable ownership Top 5
BML Investment Partners, L.P. 8.2%
FMR LLC 0%
RHUMBLINE ADVISERS 0.04%
GAMMA Investing LLC 0%
SBI Securities Co., Ltd. 0%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 21 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BML Investment Partners, L.P.
13D/G
8.2%
$19,179,460
3,724,167 shares
$0 11 Feb 2025
FMR LLC
13D/G
0%
$5,490
1,066 shares
-$13,057,691 31 Mar 2025
RHUMBLINE ADVISERS
13F
Company
13F
0.04%
$107,488
19,980 shares
31 Mar 2026
GAMMA Investing LLC
13F
Company
13F
0%
$2,464
458 shares
31 Mar 2026
SBI Securities Co., Ltd.
13F
Company
13F
0%
$1
20 shares
31 Mar 2026
Atlas Venture Fund XI, L.P.
3/4/5
10%+ Owner
class O/S missing
$140,112,473
9,798,075 shares
01 Nov 2024
ORBIMED ADVISORS LLC
3/4/5
Director, 10%+ Owner
class O/S missing
$59,522,120
5,779,071 shares
19 Sep 2022
BVF PARTNERS L P/IL
3/4/5
Other*
class O/S missing
$2,526,696
176,692 shares
29 Oct 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 20 reporting-owner rows connected to Third Harmonic Bio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
20
Largest Forms 3/4/5 holder
Atlas Venture Fund XI, L.P.
Net 12M change
$0
Latest report
11 Aug 2025
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Atlas Venture Fund XI, L.P. 10%+ Owner $140,112,473 Mixed 01 Nov 2024
ORBIMED ADVISORS LLC Director, 10%+ Owner $59,522,120 Mixed 19 Sep 2022
BVF PARTNERS L P/IL Other* $2,526,696 Filing P/S 29 Oct 2024
Natalie C. Holles CEO, Director $750,000 Mixed 11 Aug 2025
Christopher M. Murphy Chief Financial & Bus. Officer $450,000 Mixed 11 Aug 2025
Edward R. Conner Chief Medical Officer $247,500 Mixed 15 Jan 2025
Christopher Dinsmore Chief Scientific Officer $217,500 Mixed 15 Jan 2025
Julie Person Chief Administrative Officer $187,500 Mixed 15 Jan 2025
Dennis Dean Chief Nonclinical Dev. Officer $172,500 Mixed 15 Jan 2025
Jennifer Dittman Chief Operating Officer $172,500 Mixed 15 Jan 2025
David P. Bonita Director $0 Mixed 11 Aug 2025
Hans Martin Seidel Director $0 Mixed 11 Aug 2025
Iwicki Mark T. Director $0 Mixed 11 Aug 2025
Shao-Lee Lin Director Mixed 26 Oct 2022
Michael Gladstone Director, 10%+ Owner Mixed 11 Aug 2025
Adrian S. Ray Chief Scientific Officer Mixed 06 Mar 2023
Thomas P. Soloway Director Mixed 11 Aug 2025
Robert Ho Chief Financial Officer Mixed 06 Mar 2023
Robert J. Perez Director Mixed 06 Mar 2023
Geoff Mcdonough Director Mixed 27 Mar 2024

Recent insider transactions for Third Harmonic Bio, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Natalie C. Holles THRD Common Stock Other -100% -1,218,836 0 11 Aug 2025 Direct
Natalie C. Holles THRD Restricted Stock Unit Other -100% -50,000 0 11 Aug 2025 Direct
Natalie C. Holles THRD Stock Option Other -100% -998,854 0 11 Aug 2025 Direct
Michael Gladstone THRD Stock Option Other -100% -43,584 0 11 Aug 2025 Direct
Christopher M. Murphy THRD Restricted Stock Unit Other -100% -47,500 0 11 Aug 2025 Direct
Iwicki Mark T. THRD Common Stock Other -100% -128,631 0 11 Aug 2025 Direct
Iwicki Mark T. THRD Stock Option Other -100% -83,296 0 11 Aug 2025 Direct
Hans Martin Seidel THRD Common Stock Other -100% -85,753 0 11 Aug 2025 Direct
Hans Martin Seidel THRD Stock Option Other -100% -53,090 0 11 Aug 2025 Direct
Thomas P. Soloway THRD Stock Option Other -100% -120,166 0 11 Aug 2025 Direct
David P. Bonita THRD Common Stock Other -100% -5,779,071 0 11 Aug 2025 Direct
David P. Bonita THRD Stock Option Other -100% -43,584 0 11 Aug 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .